Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 3, 2014, Pages 218-226

  Marino, Donatella ^a   Leone, Francesco ^a   D'Avanzo, Francesca ^a   Ribero, Dario ^b   Capussotti, Lorenzo ^b   Aglietta, Massimo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Colorectal cancer metastases; Conversion therapy; Metastasectomy; Resection; Targeted therapies

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; REGORAFENIB; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; FATTY LIVER; GENE MUTATION; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR REGRESSION; COLORECTAL NEOPLASMS; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 84912558470     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.05.010     Document Type: Review

References (102)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27(22):3677-3683.
3. Fong Y., Fortner J., Sun R.L., Brennan M.F., Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230(3):309-318. [discussion 318-321].
4. Vigano L., Russolillo N., Ferrero A., Langella S., Sperti E., Capussotti L. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades. Ann Surg Oncol 2012, 19(6):2035-2044.
5. Cummings L.C., Payes J.D., Cooper G.S. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007, 109(4):718-726.
6. Adam R., Wicherts D.A., de Haas R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 2009, 27(11):1829-1835.
7. Van Cutsem E., Nordlinger B., Adam R., et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006, 42(14):2212-2221. European Colorectal Metastases Treatment Group.
8. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P., et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25(29):4575-4580.
9. Charnsangavej C., Clary B., Fong Y., Grothey A., Pawlik T.M., Choti M.A. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006, 13(10):1261-1268.
10. Jones R.P., Vauthey J.N., Adam R., et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br J Surg 2012, 99(9):1263-1269.
11. Grothey A., Van Cutsem E., Sobrero A., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381(9863):303-312.
12. Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30(28):3499-3506.
13. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
14. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345.
15. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947.
16. Falcone A., Masi G., Allegrini G., et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002, 20(19):4006-4014.
17. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22(1):23-30.
18. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005, 23(22):4866-4875.
19. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355(9209):1041-1047.
20. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18(1):136-147.
21. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343(13):905-914.
22. Adam R., De Gramont A., Figueras J., et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012, 17(10):1225-1239.
23. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671.
24. Folprecht G., Schuette K., Stoehlmacher J., Goekkurt E., Trarbach T. Cetuximab and FOLFOXIRI. Dose-escalation study in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2010, http://meetinglibrary.asco.org/content/2265-72 [abstr. n° 480].
25. Fornaro L., Lonardi S., Masi G., et al. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013, 24(8):2062-2067.
26. Garufi C., Torsello A., Tumolo S., et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010, 103(10):1542-1547.
27. Gruenberger T., Bridgewater J.A., Ian Chau, et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA. J Clin Oncol 2013, 31(Suppl.). [abstr. 3619].
28. Heinemann V., Fischer von Weikersthal L., Decker T., Kiani A., Vehling-Kaiser U., Al-Batran S.E. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol 2013, 31. [abstr. 3506].
29. Ku G.Y., Haaland B.A., de Lima Lopes G. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. Cancer Chemother Pharmacol 2012, 70(2):231-238.
30. Leone F., Artale S., Marino D., et al. Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases: the MetaPan study. Cancer 2013, 119(19):3429-3435. 10.1002/cncr.28223.
31. Loupakis F., Cremolini C., Masi G., et al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): results of the phase III randomized TRIBE trial. J Clin Oncol 2012, 30(Suppl. 34). [abstr. 336].
32. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-2019.
33. Saridaki Z., Androulakis N., Vardakis N., et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Br J Cancer 2012, 107(12):1932-1937.
34. Schwartzberg L.S., Rivera F., Karthaus M., et al. PEAK (study 20070509): a randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 2012, 30(Suppl. 34). [abstr. 446].
35. Wong R., Cunningham D., Barbachano Y., et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011, 22(9):2042-2048.
36. Ye L.C., Liu T.S., Ren L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013, 31(16):1931-1938.
37. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11(1):38-47.
38. van Gestel Y.R., Lemmens V.E., de Hingh I.H., et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol 2013, 20(2):371-380.
39. Jakobsson U. The ADL-staircase: further validation. Int J Rehabil Res 2008, 31(1):85-88.
40. Fried L.P., Tangen C.M., Walston J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56(3):M146-M156.
41. Aparicio T., Jouve J.L., Teillet L., et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol 2013, 31(11):1464-1470.
42. Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006, 24(25):4085-4091.
43. Sastre J., Marcuello E., Masutti B., et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005, 23(15):3545-3551.
44. Bottino V., Esposito M.G., Mottola A., et al. Early outcomes of colon laparoscopic resection in the elderly patients compared with the younger. BMC Surg 2012, 12(Suppl. 1):S8.
45. Pallis A.G., Papamichael D., Audisio R., et al. EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients. Cancer Treat Rev 2010, 36(1):83-90.
46. Boige V., Mendiboure J., Pignon J.P., et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010, 28(15):2556-2564.
47. Braun M.S., Richman S.D., Quirke P., et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008, 26(16):2690-2698.
48. Koopman M., Venderbosch S., van Tinteren H., et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009, 45(11):1999-2006.
49. Kostopoulos I., Karavasilis V., Karina M., et al. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC cancer 2009, 9:339.
50. Ikeguchi M., Arai Y., Maeta Y., Ashida K., Katano K., Wakatsuki T. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg Today 2011, 41(9):1196-1199.
51. Liu X., Cheng D., Kuang Q., Liu G., Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. PLoS One 2013, 8(3):e58489. 10.1371/journal.pone.0058489.
52. O'Dwyer P.J., Catalano R.B. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006, 24(28):4534-4538.
53. Milano G., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999, 79(3-4):627-630.
54. Amatu A., Sartore-Bianchi A., Moutinho C., et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin Cancer Res 2013, 19(8):2265-2272.
55. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27(12):2091-2096.
56. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634.
57. Bokemeyer C., Van Cutsem E., Rougier P., et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012, 48(10):1466-1475.
58. Loupakis F., Cremolini C., Salvatore L., et al. Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. Cancer 2012, 118(6):1523-1532.
59. Petrelli F., Borgonovo K., Cabiddu M., Ghilardi M., Barni S. Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Colorectal Dis 2011, 26(7):823-833.
60. Sartore-Bianchi A., Di Nicolantonio F., Nichelatti M., et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS ONE 2009, 4(10):e7287.
61. Sartore-Bianchi A., Bencardino K., Di Nicolantonio F., et al. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol 2010, 5(1):19-28.
62. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712.
63. Bardelli A., Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28(7):1254-1261.
64. Valtorta E., Misale S., Sartore-Bianchi A., et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer 2013, 133(5):1259-1265.
65. Gandhi A.K., Shi T., Li M., et al. Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PLOS ONE 2013, 8(11):e80437.
66. Siena S., Van Cutsem E., Li M., et al. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLOS ONE 2013, 8(11):e62264.
67. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11(8):753-762.
68. Misale S., Yaeger R., Hobor S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486(7404):532-536.
69. Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013, 10(8):472-484.
70. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369(11):1023-1034.
71. Peeters M., Oliner K.S., Price T.J., et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014, 32(Suppl. 3). [abstr. LBA387].
72. Tejpar S., Lenz H.J., Köhne C.H., et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: new results from the OPUS study. J Clin Oncol 2014, 32(Suppl. 3). [abstr. LBA444].
73. Ciardiello F., Lenz H.J., Kohne C.H., et al. Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): new results from the CRYSTAL trial. J Clin Oncol 2014, 32(Suppl. 3). [abstr. LBA443].
74. Stintzing S., Jung A., Rossius L., et al. Mutations within the EGFR signaling pathway: influence on efficacy in FIRE-3-A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014, 32(Suppl. 3). [abstr. 445].
75. Madi A., Fisher D., Wilson R.H., et al. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer 2012, 107(7):1037-1043.
76. Tveit K.M., Guren T., Glimelius B., et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012, 30(15):1755-1762.
77. Balin-Gauthier D., Delord J.P., Pillaire M.J., et al. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008, 98(1):120-128.
78. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28(31):4697-4705.
79. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22(7):1535-1546.
80. Woo J., Palmisiano N., Tester W., Leighton J.C. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer. Cancer 2013, 119(11):1941-1950.
81. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006, 24(31):4983-4990.
82. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15(3):460-466.
83. Rubbia-Brandt L., Lauwers G.Y., Wang H., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010, 56(4):430-439.
84. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005, 200(6):845-853.
85. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24(13):2065-2072.
86. Van Buren G., Yang A.D., Dallas N.A., et al. Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 2008, 26(11):1836-1842.
87. Hubert C., Sempoux C., Humblet Y., et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxf) 2013, 15(11):858-864.
88. Li D.B., Ye F., Wu X.R., et al. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol 2013, 19(5):761-768.
89. Ribero D., Wang H., Donadon M., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110(12):2761-2767.
90. Chun Y.S., Laurent A., Maru D., Vauthey J.N. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009, 10(3):278-286.
91. Cleary J.M., Tanabe K.T., Lauwers G.Y., Zhu A.X. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 2009, 14(11):1095-1105.
92. Kishi Y., Zorzi D., Contreras C.M., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 2010, 17(11):2870-2876.
93. Folprecht G., Grothey A., Alberts S., Raab H.R., Kohne C.H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16(8):1311-1319.
94. Rubbia-Brandt L., Giostra E., Brezault C., et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007, 18(2):299-304.
95. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 2006, 24(24):3939-3945.
96. Ferrero A., Langella S., Russolillo N., Vigano L., Lo Tesoriere R., Capussotti L. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg 2012, 16(4):806-814.
97. Adams R.B., Aloia T.A., Loyer E., Pawlik T.M., Taouli B., Vauthey J.N. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxf) 2013, 15(2):91-103. Americas Hepato-Pancreato-Biliary Association, Society of Surgical Oncology, Society for Surgery of the Alimentary Tract.
98. Tampellini M., Ottone A., Bellini E., et al. The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study. Oncologist 2012, 17(11):1430-1438.
99. de Cuba E.M., Kwakman R., Knol D.L., Bonjer H.J., Meijer G.A., Te Velde E.A. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev 2013, 39(4):321-327.
100. Sourrouille I., Mordant P., Maggiori L., et al. Long-term survival after hepatic and pulmonary resection of colorectal cancer metastases. J Surg Oncol 2013, 108:220-224.
101. Gerlinger M., Rowan A.J., Horswell S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366(10):883-892.
102. Salvatore L., Loupakis F., Cremolini C., et al. FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients. J Clin Oncol 2012, 30(Suppl.). [absr 3585].